C. Delaney

Deverra Therapeutics is a clinical-stage biotechnology company focused on developing off-the-shelf, allogeneic cell therapies derived from umbilical cord blood. Founded by Dr. Colleen Delaney, the company utilizes a proprietary platform to expand and differentiate cord blood-derived stem cells into various immune effector cells, including natural killer (NK) cells, monocytes, and macrophages. Their lead programs target hematologic malignancies such as acute myeloid leukemia and infectious diseases, including COVID-19. Deverra's unique manufacturing approach involves pooling donors to achieve scalability and cost-effectiveness, aiming to provide universally accessible cellular immunotherapies. The company has established significant partnerships, including an exclusive rights agreement with Coeptis Therapeutics for its immuno-oncology platform.